Chicago, IL - ASCO 2012 Annual Meeting: - -96291/LBA8500^--Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma**A. Hauschild  during the Oral: Melanoma session at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Monday June 4, 2012.  Over 31,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Todd Buchanan 2012 Technical Questions:; ASCO Contact:
Powered by SmugMug Owner Log In